Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)

Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Depart...

Full description

Bibliographic Details
Main Authors: Khalifa E. Sharquie, Adil A. Noaimi, Ahmed G. Al-Ghazzi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-07-01
Series:Journal of Dermatology and Dermatologic Surgery
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352241015000171
_version_ 1818352435206291456
author Khalifa E. Sharquie
Adil A. Noaimi
Ahmed G. Al-Ghazzi
author_facet Khalifa E. Sharquie
Adil A. Noaimi
Ahmed G. Al-Ghazzi
author_sort Khalifa E. Sharquie
collection DOAJ
description Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects.
first_indexed 2024-12-13T18:53:35Z
format Article
id doaj.art-e72d694c7a3e4538b7fbb5683534a8c3
institution Directory Open Access Journal
issn 2352-2410
language English
last_indexed 2024-12-13T18:53:35Z
publishDate 2015-07-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Dermatology and Dermatologic Surgery
spelling doaj.art-e72d694c7a3e4538b7fbb5683534a8c32022-12-21T23:34:53ZengWolters Kluwer Medknow PublicationsJournal of Dermatology and Dermatologic Surgery2352-24102015-07-0119210811310.1016/j.jdds.2014.10.001Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)Khalifa E. Sharquie0Adil A. Noaimi1Ahmed G. Al-Ghazzi2Department of Dermatology, College of Medicine, University of Baghdad, Iraqi and Arab Board for Dermatology and Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, IraqDepartment of Dermatology, College of Medicine, University of Baghdad, Iraqi and Arab Board for Dermatology and Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, IraqDepartment of Dermatology and Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, IraqBackground: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects.http://www.sciencedirect.com/science/article/pii/S2352241015000171Cutaneous leishmaniasisPodophyllinTreatment
spellingShingle Khalifa E. Sharquie
Adil A. Noaimi
Ahmed G. Al-Ghazzi
Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
Journal of Dermatology and Dermatologic Surgery
Cutaneous leishmaniasis
Podophyllin
Treatment
title Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
title_full Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
title_fullStr Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
title_full_unstemmed Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
title_short Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
title_sort treatment of cutaneous leishmaniasis by topical 25 podophyllin solution single blinded therapeutic controlled study
topic Cutaneous leishmaniasis
Podophyllin
Treatment
url http://www.sciencedirect.com/science/article/pii/S2352241015000171
work_keys_str_mv AT khalifaesharquie treatmentofcutaneousleishmaniasisbytopical25podophyllinsolutionsingleblindedtherapeuticcontrolledstudy
AT adilanoaimi treatmentofcutaneousleishmaniasisbytopical25podophyllinsolutionsingleblindedtherapeuticcontrolledstudy
AT ahmedgalghazzi treatmentofcutaneousleishmaniasisbytopical25podophyllinsolutionsingleblindedtherapeuticcontrolledstudy